Cigana Cristina, Castandet Jérôme, Sprynski Nicolas, Melessike Medede, Beyria Lilha, Ranucci Serena, Alcalá-Franco Beatriz, Rossi Alice, Bragonzi Alessandra, Zalacain Magdalena, Everett Martin
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Antabio SAS, Labège, France.
Front Microbiol. 2021 Jan 12;11:620819. doi: 10.3389/fmicb.2020.620819. eCollection 2020.
Chronic infection by in cystic fibrosis (CF) patients is a major contributor to progressive lung damage and is poorly treated by available antibiotic therapy. An alternative approach to the development of additional antibiotic treatments is to identify complementary therapies which target bacterial virulence factors necessary for the establishment and/or maintenance of the chronic infection. The elastase (LasB) has been suggested as an attractive anti-virulence target due to its extracellular location, its harmful degradative effects on host tissues and the immune system, and the potential to inhibit its activity using small molecule inhibitors. However, while the relevance of LasB in acute infection has been demonstrated, it is still unclear whether this elastase might also play a role in the early phase of chronic lung colonization. By analyzing clinical clonal isolates from a CF patient, we found that the isolate RP45, collected in the early phase of persistence, produces large amounts of active LasB, while its clonal variant RP73, collected after years of colonization, does not produce it. When a mouse model of persistent pneumonia was used, deletion of the gene in RP45 resulted in a significant reduction in mean bacterial numbers and incidence of chronic lung colonization at Day 7 post-challenge compared to those mice infected with wild-type (wt) RP45. Furthermore, deletion of in strain RP45 also resulted in an increase in immunomodulators associated with innate and adaptive immune responses in infected animals. In contrast, deletion of the gene in RP73 did not affect the establishment of chronic infection. Overall, these results indicate that LasB contributes to the adaptation of to a persistent lifestyle. In addition, these findings support pharmacological inhibition of LasB as a potentially useful therapeutic intervention for -infected CF patients prior to the establishment of a chronic infection.
囊性纤维化(CF)患者中的慢性感染是导致进行性肺损伤的主要因素,现有抗生素治疗对此疗效不佳。开发额外抗生素治疗方法的另一种途径是确定针对慢性感染建立和/或维持所必需的细菌毒力因子的补充疗法。铜绿假单胞菌弹性蛋白酶(LasB)因其细胞外定位、对宿主组织和免疫系统的有害降解作用以及使用小分子抑制剂抑制其活性的潜力,被认为是一个有吸引力的抗毒力靶点。然而,虽然LasB在急性铜绿假单胞菌感染中的相关性已得到证实,但尚不清楚这种弹性蛋白酶是否也可能在慢性肺部定植的早期阶段发挥作用。通过分析一名CF患者的临床铜绿假单胞菌克隆分离株,我们发现,在持续感染早期收集的分离株RP45产生大量活性LasB,而在定植多年后收集的其克隆变体RP73则不产生。当使用持续性肺炎小鼠模型时,与感染野生型(wt)RP45的小鼠相比,RP45中铜绿假单胞菌基因的缺失导致在攻击后第7天平均细菌数量显著减少,慢性肺部定植的发生率降低。此外,RP45菌株中铜绿假单胞菌基因的缺失还导致感染动物中与先天和适应性免疫反应相关的免疫调节剂增加。相比之下,RP73中铜绿假单胞菌基因的缺失不影响慢性感染的建立。总体而言,这些结果表明LasB有助于铜绿假单胞菌适应持续感染的生活方式。此外,这些发现支持对LasB进行药理抑制,作为在慢性感染建立之前对铜绿假单胞菌感染的CF患者进行潜在有用的治疗干预措施。